Evidence map›Paper›PMID 38202844›Full record

ArticleMolecules (Basel, Switzerland)2024

Paeonol Attenuates Atherosclerosis by Inhibiting Vascular Smooth Muscle Cells Senescence via SIRT1/P53/TRF2 Signaling Pathway.

Min Zhou, Xiaolin Ma, Menglong Gao, Hongfei Wu, Yarong Liu, Xiaoyan Shi, Min Dai

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Paeonol attenuates atherosclerosis by inhibiting mTORJournal of translational internal medicine · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Min ZhouCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Xiaolin MaCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Menglong GaoCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Hongfei WuCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Yarong LiuCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Xiaoyan ShiCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Min DaiCollege of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
Anhui University of Traditional Chinese Medicine · CN

Funding

National Natural Science Foundation of China 82174014Natural Science Foundation of Anhui Province 2308085QH296Natural Science Program of Education Department of Anhui Province 2022AH050518
6 · The paper itself

Abstract

Atherosclerosis is a chronic inflammatory disease leading to various vascular diseases. Vascular smooth muscle cell (VSMC) senescence promotes atherosclerotic inflammation and the formation of plaque necrosis core, in part through telomere damage mediated by a high-fat diet. Our previous research found that paeonol, a potential anti-inflammatory agent extracted from Cortex Moutan, could significantly improve VSMCs dysfunction. However, the impact of paeonol on the senescence of VSMCs remains unexplored. This study presents the protective effects of paeonol on VSMCs senescence, and its potential activity in inhibiting the progression of atherosclerosis in vivo and in vitro. Sirtuin 1 (SIRT1) is a nuclear deacetylase involved in cell proliferation, senescence, telomere damage, and inflammation. Here, SIRT1 was identified as a potential target of paeonol having anti-senescence and anti-atherosclerosis activity. Mechanistic studies revealed that paeonol binds directly to SIRT1 and then activates the SIRT1/P53/TRF2 pathway to inhibit VSMCs senescence. Our results suggested that SIRT1-mediated VSMCs senescence is a promising druggable target for atherosclerosis, and that pharmacological modulation of the SIRT1/P53/TRF2 signaling pathway by paeonol is of potential benefit for patients with atherosclerosis.

Indexed as

AcetophenonesAtherosclerosisSirtuinsHumansInflammationMuscle, Smooth, VascularSignal TransductionSirtuin 1Tumor Suppressor Protein p53AcetophenonespaeonolSIRT1 protein, humanSirtuin 1SirtuinsTumor Suppressor Protein p53atherosclerosiscell senescencepaeonolSIRT1vascular smooth muscle cells

Identifiers

PMID38202844
PMCPMC10780795
OpenAlexW4390586526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.